MRK Stock Price Today (July 2026) — Merck & Co., Inc. Analysis & Key Metrics 2026-07-17
Merck & Co., Inc. (MRK) is trading at $127.50, down 0.10% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $130.39 (2.3% upside).
- Volatility remains elevated (26.99% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (4.90% YoY) alongside significant competitive pressures.
MRK Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Merck & Co., Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $360.84B
P/E Ratio
Forward P/E: 13.42
Revenue Growth
Year over Year
Analyst Target
+2.3% upside potential
Key Investor Questions About MRK
What investors need to know before buying
Based on current market data, MRK presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 57.91)
- Fundamentals say: Caution warranted (high leverage concerns)
MRK's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRK investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $49.12B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, MRK stock traded between $76.66 and $130.29—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 26.99% annualized volatility and β=0.34, the stock exhibits low sensitivity to market moves—making MRK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
The Real Question Buried Inside Merck Stock's Premium Price
The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.
Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.
Personalis stock reversed lower Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
New Cholesterol Pill, Earnings Growth Boost Merck Shares
Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.
MSD wins FDA approval for cholesterol pill to help plug Keytruda void
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.
GSK shelves cough drug acquired in $2B deal
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
Why Is PSNL Stock Up 5% After-Hours?
Personalis has hired investment banks Centerview and TD Securities, along with law firm Cooley, to review its strategic options, according to a report in Street Insider.
Frequently Asked Questions
Common investor questions about Merck & Co., Inc.
Merck & Co., Inc. (MRK) is currently trading at $127.50. The RSI (14-day) is at 57.9, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $130.39 implies 2.3% upside from current levels. Volatility is moderate at 27.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Merck & Co., Inc. (MRK): The trailing P/E ratio is 35.92, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 13.42, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 6.35, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 6.86. Price-to-Sales is 4.79. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering MRK, the consensus price target is $130.39. This represents a 2.3% upside from the current price of $127.50. The range spans from a low target of $100.00 to a high target of $150.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Merck & Co., Inc. (MRK) pays a dividend with a current yield of approximately 2.67%. The annualized dividend rate is $3.28 per share. The payout ratio is 93.5%, which is relatively high—earnings cover the dividend but there's limited room for increases. The most recent ex-dividend date was 2026-06-15T00:00:00.000Z.
Key risks for Merck & Co., Inc. (MRK) investors include: 1. Moderate volatility (27.0% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 106.94) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Merck & Co., Inc.'s (MRK) current debt and financial health profile: Total debt stands at $49.12B. The debt-to-equity ratio is 106.94, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.30, indicating adequate short-term liquidity. The quick ratio is 0.70. The company holds $5.70B in cash and equivalents. Free cash flow is positive at $14.05B, providing a cushion for debt servicing and shareholder returns.